Serum levels of IL-6 are usually elevated in mCRPC patients and have been shown to play an important role in driving aggressive PCa phenotypes, cancer progression, metastasis, epithelial-mesenchymal transition (EMT), drug resistance, and cancer cell survival by networking with multiple signaling pathways. This evidence concerns the gene IL6 and posterior cortical atrophy.